| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vivo |
Mesoside K's average peak concentration and appearance time in rats given total saponins from Intolerantia were 511.11±234.07 ng/mL and 0.46 h, respectively, following oral administration. Hosenkoside A has a terminal half-life of 4.96±1.75 hours [1].
|
|---|---|
| Animal Protocol |
Male Wistar rats (220 ± 20 g) were fasted for 12 hours. The total saponins of Semen Impatients, containing hosenkoside K at a dose of 31.6 mg/kg (equivalent to an oral dose of 300 mg/kg total saponins), were dissolved in 0.5% methyl cellulose and orally administered to rats via gastric gavage.[1]
Blood samples (approximately 0.20 mL) were collected from the suborbital vein into heparinized tubes at pre-dose (0 min) and at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours after dosing.[1] Plasma was harvested by centrifugation and stored at -80°C until analysis.[1] |
| ADME/Pharmacokinetics |
After oral administration of total saponins from daffodils (equivalent to 31.6 mg/kg hosenkoside K) to rats, the mean peak plasma concentration (Cmax) was 101.72 ± 24.25 ng/mL. [1] The time to peak concentration (Tmax) was 0.46 ± 0.19 hours. [1] The elimination half-life (t1/2) was 4.96 ± 1.75 hours. [1] The mean residence time (MRT) was 6.02 ± 1.92 hours. [1] The area under the plasma concentration-time curve (from zero time to the last measurable concentration) was 386.63 ± 162.27 ng·h/mL. [1] The area under the plasma concentration-time curve (from zero time to infinity) was 459.32 ± 118.97 ng·h/mL. [1]
The apparent clearance (CL/F) was 69.98 ± 21.92 L/h/kg. [1] The apparent volume of distribution (V/F) was 511.11 ± 234.07 L/kg. [1] The plasma concentration-time curve showed a bimodal distribution, which may be related to enterohepatic circulation or drug interactions. [1] |
| References | |
| Additional Infomation |
Hosenkoside K has been reported in literature. Hosenkoside K is a saponin compound belonging to bacaridine glycosides and is considered one of the main active ingredients of Impatiens balsamina Linn. [1] It is listed as a marker compound for quality control of Impatiens balsamina semen in the Chinese Pharmacopoeia. [1] We developed and validated a rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantitative analysis of Hosenkoside K and Hosenkoside A in rat plasma. [1] The limit of quantification (LLOQ) of Hosenkoside K in rat plasma is 5 ng/mL. [1] The validated method has good precision, accuracy, recovery and stability for the analysis of Hosenkoside K. [1]
|
| Molecular Formula |
C54H92O25
|
|---|---|
| Molecular Weight |
1141.29330062866
|
| Exact Mass |
1140.592
|
| CAS # |
160896-49-1
|
| PubChem CID |
102004887
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.639
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
79
|
| Complexity |
2020
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
C[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@@H]2CC[C@@]3(CC[C@@]4([C@@H]([C@H]3O)CC[C@H]5[C@]4(CC[C@@H]6[C@@]5(CC[C@@H]([C@@]6(C)CO[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)C)C)C)CO2
|
| InChi Key |
JWINIHBXRZXFKL-SGBJXWCQSA-N
|
| InChi Code |
InChI=1S/C54H92O25/c1-23(20-71-46-41(67)37(63)33(59)26(16-55)74-46)25-8-13-54(22-72-25)15-14-52(4)24(45(54)70)6-7-31-50(2)11-10-32(51(3,30(50)9-12-53(31,52)5)21-73-47-42(68)38(64)34(60)27(17-56)75-47)78-49-44(40(66)36(62)29(19-58)77-49)79-48-43(69)39(65)35(61)28(18-57)76-48/h23-49,55-70H,6-22H2,1-5H3/t23-,24+,25-,26+,27+,28+,29+,30+,31+,32-,33+,34+,35+,36+,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51-,52+,53+,54+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2S)-2-[(1R,2S,2'S,4aR,4bR,6aR,7R,8S,10aR,10bR,12aS)-8-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-1-hydroxy-4a,4b,7,10a-tetramethyl-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]spiro[3,4,5,6,6a,8,9,10,10b,11,12,12a-dodecahydro-1H-chrysene-2,5'-oxane]-2'-yl]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~87.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8762 mL | 4.3810 mL | 8.7620 mL | |
| 5 mM | 0.1752 mL | 0.8762 mL | 1.7524 mL | |
| 10 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
